Literature DB >> 2905659

Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin.

G Schettini1, T Florio, G Magri, M Grimaldi, O Meucci, E Landolfi, A Marino.   

Abstract

The involvement of somatostatin in the organization of cognitive functions was studied. We assessed changes in learning and memory processes by studying the effects of cysteamine, a compound that decreases somatostatin-like immunoreactivity in the brain, somatostatin and the potent somatostatin analogue, SMS 201-995, on active avoidance behaviour, assessed with a shuttle box apparatus, or on passive avoidance behaviour. Cysteamine induced a loss of the conditioned active avoidance response acquired after 3 weeks of daily trials. The effect was observed 2 h (-29%) and 4 h (-51%) after cysteamine treatment (300 mg/kg s.c.) and disappeared after 24 h. Intracerebroventricular administration of somatostatin or SMS 201-995 to cysteamine-treated rats significantly reversed the cysteamine effects on the conditioned avoidance responses. Similar results were obtained on passive avoidance behaviour. We also investigated the effect of cysteamine treatment on brain somatostatin-sensitive adenylate cyclase. We observed that adenylate cyclase activity in the frontal cortex of cysteamine-pretreated animals was more sensitive to inhibition by the SRIF analogue, SMS 201-995, than it was in control animals. This effect was observed at concentrations of SMS 201-995 that were ineffective in control tissue. These results show that disruption of somatostatinergic transmission affects cognitive functions of rats.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905659     DOI: 10.1016/0014-2999(88)90536-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Novel proline endopeptidase inhibitors do not modify Abeta40/42 formation and degradation by human cells expressing wild-type and swedish mutated beta-amyloid precursor protein.

Authors:  A Petit; H Barelli; P Morain; F Checler
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.

Authors:  William L Neumann; Karin E Sandoval; Shirin Mobayen; Mahsa Minaeian; Stephen G Kukielski; Khush N Srabony; Rafael Frare; Olivia Slater; Susan A Farr; Michael L Niehoff; Audrey Hospital; Maria Kontoyianni; A Michael Crider; Ken A Witt
Journal:  RSC Med Chem       Date:  2021-05-26

3.  Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity.

Authors:  Christian Kluge; Christian Stoppel; Csaba Szinyei; Oliver Stork; Hans-Christian Pape
Journal:  Learn Mem       Date:  2008-04-03       Impact factor: 2.460

4.  Somatostatinergic systems: an update on brain functions in normal and pathological aging.

Authors:  Guillaume Martel; Patrick Dutar; Jacques Epelbaum; Cécile Viollet
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-06       Impact factor: 5.555

Review 5.  Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.

Authors:  Federico Gatto; Federica Barbieri; Marica Arvigo; Stefano Thellung; Jessica Amarù; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

6.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

Review 7.  Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity.

Authors:  Monika Liguz-Lecznar; Joanna Urban-Ciecko; Malgorzata Kossut
Journal:  Front Neural Circuits       Date:  2016-06-30       Impact factor: 3.492

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.